Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

PURPOSE: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist (LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with tiotropium (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Chron Obstruct Pulmon Dis
Main Authors: Miravitlles, Marc, Gáldiz, Juan B, Huerta, Alicia, Villacampa, Alba, Carcedo, David, Garcia-Rio, Francisco
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723026/
https://ncbi.nlm.nih.gov/pubmed/26848262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S94006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados